Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma

Cancer

Volumn 115, Issue 12, 2009, Pages 2652-2659

  Calabrò, Fabio ^a   Lorusso, Vito ^b   Rosati, Gerardo ^c   Manzione, Luigi ^c   Frassineti, Luca ^d   Sava, Teodoro ^e   Di Paula, Eugenio Donato ^a   Alonso, Silvia ^a   Sternberg, Cora N ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b VITO FAZZI HOSPITAL   (Italy)

^c SAN CARLO HOSPITAL   (Italy)

^d MORGAGNI PIERANTONI HOSPITAL   (Italy)

^e UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Gemcitabine; Outpatient regimen; Paclitaxel; Urothelial carcinoma

Indexed keywords

CHLORPHENIRAMINE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; RANITIDINE;

ADULT; AGED; ANEMIA; ARTICLE; BLADDER METASTASIS; BLEEDING; BONE METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELENA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; UROGENITAL TRACT CANCER; UROGENITAL TRACT CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; URINARY BLADDER NEOPLASMS;

EID: 67649229152     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24313     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Sternberg CN, Yagoda A, Scher HI, et al. M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy, and patterns of response and relapse. Cancer. 1989;64:2448-2458.
3. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068-3077. (Pubitemid 30677086)
4. Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 2007;69 (1 suppl):62-79. (Pubitemid 46186484)
5. von der Maase H. Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev Anticancer Ther. 2003;3:11-19. (Pubitemid 36204435)
6. Castagneto B, Zai S, Marenco D, et al. Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment. Oncology. 2004;67:27-32. (Pubitemid 39370347)
7. Pollera CF, Ceribelli A, Crecco M, Calabresi F. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol. 1994;5:182-184. (Pubitemid 24062575)
8. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997;15:3394-3398. (Pubitemid 27485860)
9. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 1997;15:3441-3445. (Pubitemid 27527715)
10. Lorusso V, Pollera CF, Antimi M, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur J Cancer. 1998;34:1208-1212. (Pubitemid 28342111)
11. Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol. 2000;18:2780-2787. (Pubitemid 30463562)
12. Roth BJ, Dreicer R, Einhorn LH. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 1994;12:2264-2270. (Pubitemid 24346693)
13. Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with every-2-week gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer. 2001;92:2993-2998. (Pubitemid 33136193)
14. Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
15. Simon RM. Design and conduct of clinical trials. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 3rd ed. Philadelphia, Pa: JB Lippincott; 1989: 396-422.
16. Guardino AE, Srinivas S. Gemcitabine and paclitaxel as second line chemotherapy for advanced urothelial malignancies [abstract]. Proc Am Soc Clin Oncol. 2002;21. Abstract 2413.
17. Fechner G, Siener R, Reimann M, Kobalz L, Albers P, German Association of Urologic Oncology (AUO) Bladder Cancer Study Group. Randomised phase II trial of gemcitabine, paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract. 2006;60:27-31.
18. Kaufman DS, Carducci MA, Kuzel TM, et al. A multiinstitutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol. 2004;22:393-397. (Pubitemid 40500816)
19. Meluch AA, Greco FA, Burris HA3, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2001;19:3018-3024. (Pubitemid 32565438)
20. Li J, Juliar B, Yiannoutsos C, et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol. 2005;23:1185-1191. (Pubitemid 46202275)
21. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173-3181. (Pubitemid 29470648)
22. Bellmunt J, Ribas A, Eres N, et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer. 1997;80:1966-1972. (Pubitemid 27479792)
23. Linardou H, Aravantinos G, Efstathiou E, et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: phase II study of the Hellenic Co-operative Oncology Group. Urology. 2004;64:479-484. (Pubitemid 39200741)
24. Bellmunt J, de Wit R, Albanell J, Baselga J. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur J Cancer. 2001;37:2212-2215.
25. Vaughn DJ, Malkowicz SB, Zoltick B, et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol. 1998;16:255-260. (Pubitemid 28041606)
26. Carles J, Nogue M, Domenech M, et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology. 2000;59:24-27. (Pubitemid 30435831)
27. Small EJ, Lew D, Redman BG, et al. Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional cell carcinoma: the importance of survival as a clinical trial endpoint. J Clin Oncol. 2000;18:2537-2544. (Pubitemid 30432519)
28. Vaughn DJ, Manola J, Dreicer R, See W, Levitt R, Wilding G. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer. 2002;95:1022-10227.
29. Dreicer R, Manola J, Roth BJ, et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer. 2004;100:1639-1645.
30. Carles J, Esteban E, Climent M, et al. Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann Oncol. 2007;18:1359-1362. (Pubitemid 47305010)